VSTMVerastem, Inc.Signing up patients
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Worry score12
Score over time
- Stage
- Phase 2
- Patients
- 105 (planned)
- Started
- Jul 22, 2026
- Main results expected
- Jun 2027
- Fully finished
- Dec 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1
Measured over: 6 months
To characterize the safety and tolerability of VS-7375 monotherapy administered on a daily oral schedule in participants with KRAS G12D-mutated NSCLC
Measured over: 6 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["contactsLocationsModule","statusModule"]}
Trial ID NCT07659782 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC